This poster (PDF: ADF Surveys Poster) was recently presented at the Academy Health Annual Research Meeting. Check out the link for detailed survey results and principal findings.
Authors: John R. Brown, Svetla Slavova, Nabarun Dasgupta, Patricia R. Freeman
Abuse-deterrent formulation (ADF) opioids represent an opportunity to deter the misuse and abuse of opioids. In the clinical setting, decisions by physicians and other practitioners directly impact who receives a prescription for an ADF opioid versus a traditional formulation. The identification of factors associated with ADF opioid prescribing is critical to inform clinical guidelines and policymaking.
Some key findings:
- Percentages of physicians who reported having prescribed the products ranged from 11.4% (Hysingla® ER) to 49.6% (OxyContin®).
- Less than half of pharmacists (43.2%) and physicians (30.6%) reported a belief that ADFs are an effective or very effective strategy in mitigating the misuse/abuse of prescription opioids.
- Most pharmacists (66.6%) and physicians (73.7%) indicated they would support legislation which mandates third-party coverage of ADFs
To find out more information about this project, view the study page located here.
